Page 115 - Security Act News Today

Stacker investigated the way the idea of privacy has changed in the U.S. during the last...

Trade-off.

On the last day of its term, the Supreme Court stops the Environmental Protection Agency from making policy without express congressional authorization.

The Global Expression Report 2022, an annual look at the rights to freedom of expression and information across the world, has said that Bangladesh's freedoms have worsened in the last ten years and are now considered to be "in crisis". The report, which tracks freedoms of expression across 161 countries via 25 indicators, warned that globally freedoms were "more precarious

The Supreme Court saved a crucial decision for the last day of its term, ruling 6–3 in West Virginia v. Environmental Protection Agency that the Clean Air Act does not allow the EPA to move from regulating individual power plants to regulating regional emissions through its interpretation of the Clean Power Plan. The opinion, written […]

In Ruan v. United States, Supreme Court held mens rea supporting Controlled Substances Act violation applies to affirmative defense. Sentence syntax is similar to operative sentences in federal Anti-Kickback Statute, may affect False Claims Act cases based on AKS violation.

A first-ever live auction for wetland mitigation credits will be held Friday (July 1, 2022) hosted by the Sout...

State legislators have failed miserably in their goal of expanding New York’s use of green power.

Listen as Donna Ritson, President of DDR Communications. Ritson discusses how the COVID-19 pandemic disrupted pharmaceutical production and how that disruption affected the industry. She also highlights that, more than ever before, pharma companies are open to input and cooperation from OEMs to find ways to prevent this deep disruption in the future.

Listen as Donna Ritson, President of DDR Communications. Ritson discusses how the COVID-19 pandemic disrupted pharmaceutical production and how that disruption affected the industry. She also highlights that, more than ever before, pharma companies are open to input and cooperation from OEMs to find ways to prevent this deep disruption in the future.